Company intelligence
iOnctura
Developing precision small molecules to combat hard-to-treat tumors.
Biotechnology Research
Geneve, CH
32 employees
Founded 2017
1 public signals
About iOnctura
iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve healthspans, changing the outlook for patients and their families. Two therapeutic candidates have progressed into mid-stage clinical development: roginolisib is the first allosteric modulator of PI3Kδ and cambritaxestat is the only autotaxin inhibitor in clinical development to treat cancer.
Verified activity
Signals from iOnctura
1 published signal